Tvardi Therapeutics (NASDAQ:TVRD) Downgraded by Cantor Fitzgerald to Neutral

Cantor Fitzgerald downgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from an overweight rating to a neutral rating in a research report sent to investors on Monday morning, MarketBeat reports.

A number of other analysts also recently weighed in on the company. Raymond James Financial started coverage on Tvardi Therapeutics in a research note on Monday, July 14th. They issued an “outperform” rating and a $62.00 price target on the stock. Barclays started coverage on Tvardi Therapeutics in a research note on Monday. They issued an “overweight” rating and a $61.00 price target on the stock. Piper Sandler downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday. Finally, Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Saturday, September 27th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $46.17.

Tvardi Therapeutics Trading Down 83.9%

Shares of TVRD stock opened at $6.69 on Monday. Tvardi Therapeutics has a twelve month low of $5.65 and a twelve month high of $43.65. The company has a 50 day moving average of $31.63.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Institutional Trading of Tvardi Therapeutics

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics in the second quarter valued at $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at $43,000. Headlands Technologies LLC purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at $80,000. New York State Common Retirement Fund purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at $92,000. Finally, Bank of America Corp DE purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at $399,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.